Related Experiment Video
Updated: Jun 6, 2026

Three-Dimensional Imaging of Tumor-Bearing Tissue Using the Iterative Bleaching Extends Multiplexity Approach
Published on: April 25, 2025
Infliximab administered with shortened infusion times in a specialized IBD infusion unit: a prospective cohort study
Gert Van Assche1, Séverine Vermeire, Maja Noman
1Division of Gastroenterology, Leuven University Hospitals, 49 Herestraat, 3000-Leuven, Belgium. Gert.vanassche@uzleuven.be
Background And Aims:
Biological therapy with anti TNF agents requires parenteral administration and in the case of infliximab this involves in hospital treatment. We aimed to prospectively assess the safety and tolerance of infliximab infusion in patients with IBD in a specialized unit adhering to strict standard operation procedures including switch to accelerated 1h infusions.
Methods:
A prospective audit of a referral center IBD infusion unit was performed. We recorded infusion times and all adverse events including hypersensitivity reactions. Patients were also polled about the impact of the treatment on quality of life (QOL).
Results:
On 20 consecutive days 177 patients were treated with infliximab and all participated. Of those infliximab 117 received 1h infusions and 4 (2.2%) had an immediate infusion reaction. Median time on unit was optimal for those with 1h infusions [1:35 h (IQR: 1:25-1:50)] without an increased risk of infusion reactions. Prophylactic therapy significantly increased the time on unit [3:20 h (IQR: 2:50-3:45), p<0.001]. Patients reported a high global satisfaction and a good tolerability of the infusions with a considerable or strong impact on studies, work or QOL in one third.
Conclusions:
A dedicated IBD infusion unit can achieve high quality of care and shortened 1h infliximab infusions are well tolerated in patients with scheduled maintenance therapy.
More Related Videos
07:38Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
08:43Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase (G6PI)-Induced RA Mice
Published on: January 31, 2020
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...